Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + gemcitabine
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Surufatinib + gemcitabine is a combination therapy under investigation for the treatment of various solid tumors, including pancreatic cancer. Surufatinib is an oral, small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptor 1 (FGFR1), and colony stimulating factor 1 receptor (CSF-1R). This dual mechanism blocks tumor angiogenesis and modulates the tumor immune microenvironment by regulating tumor-associated macrophages[6][1]. Gemcitabine is a nucleoside analog antimetabolite that interferes with DNA synthesis by incorporating into DNA and causing masked chain termination, leading to cell death[8][3]. The combination aims to leverage both antiangiogenic/immune-modulating effects of surufatinib and the cytotoxic activity of gemcitabine. Surufatinib is developed and marketed in China by HUTCHMED under the brand name SULANDA[1].
- Other names
- surufatinib + gemcitabine
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on surufatinib + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + gemcitabine.